.png)
Multiple Sclerosis Drugs Treatment Market by Type andApplication- Global Industry Analysis & Forecast to 2027
Published On : November 2020 Pages : 147 Category: Pharma & Healthcare Report Code : HC1213777
SEGMENTS & REGIONS:
- Regions: North America, Europe, Asia- Pacific, Latin America, Middle East & Africa
Multiple Sclerosis Drugs TreatmentMarket by Type(Immunomodulator,Interferon,Immunosuppressant)Application (Retail Pharmacy,Hospital Pharmacy,Online Pharmacy)- Global Industry Analysis & Forecast to 2027
Industry Outlook and Trend Analysis
Multiple Sclerosis Drugs TreatmentMarket has encountered significant development over the recent years and is anticipated to grow tremendously over the forecast period.Multiple sclerosis (MS) is an intricate and incapacitating persistent sensory system disease.This disease acute active focal anxious white issue has different fiery demyelinating spots, old injuries because of glial fiber hyperplasia and calcification spots, with numerous sores, reduction, repeat of the course of infection as the characteristics, various sclerosis drug therapy can lessen the repeat pace of this illness and hinder the cycle of inability.
Drivers and Restraints
Top-down and bottom-up approaches are used to validate the global market size market and estimate the market size for company, regions segments, type segments and applications (end users). In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub segments listed in this report. Extensive qualitative and further quantitative analysis is also done from all the numbers arrived at in the complete market engineering process to list key information throughout the report.
Regional Insights
The data for 2021 is an estimate, based on the history data and the integrated view of industry experts, manufacturers, distributors and end users etc.
By Region
- North America
- S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia-Pacific
- SouthAmerica
- Brazil
- Argentina
- Columbia
- Rest of South America
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Nigeria
- South Africa
- Rest of MEA
Competitive Analysis
The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.
- Roche
- Teva Pharmaceutical
- Pfizer
- Biogen
- Merck
- Bayer
- Novartis
- Acorda Therapeutics
- Sanofi
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2021 to 2027?
- What will be the industry market growth from 2017 to 2027?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
· Multiple Sclerosis Drugs Treatment Market, ByType, Estimates and Forecast, 2017-2027 ($Million)
o Immunomodulator
o Interferon
o Immunosuppressant
· Multiple Sclerosis Drugs Treatment Market, ByApplication, Estimates and Forecast, 2017-2027 ($Million)
o Retail Pharmacy
o Hospital Pharmacy
· Multiple Sclerosis Drugs Treatment Market, By Key Players, Estimates and Forecast, 2017-2027 ($Million)
o Shin-Etsu
o Hitachi Metals Group
o Jingci Material Science
o TDK
o Beijing Zhong Ke San Huan Hi-Tech
o VAC
o Yunsheng Company
o JL MAG
o YSM
o ZHmag
· Multiple Sclerosis Drugs Treatment Market, By Region, Estimates and Forecast, 2017-2027 ($Million)
o North America
§ North America Multiple Sclerosis Drugs Treatment Market, By Country
o U.S. Multiple Sclerosis Drugs Treatment Market
o Canada Multiple Sclerosis Drugs Treatment Market
o Mexico Multiple Sclerosis Drugs Treatment Market
o Europe
§ Europe Multiple Sclerosis Drugs Treatment Market, By Country
· Germany Multiple Sclerosis Drugs Treatment Market
o UK Multiple Sclerosis Drugs Treatment Market
o France Multiple Sclerosis Drugs Treatment Market
o RussiaMultiple Sclerosis Drugs Treatment Market
o Italy Multiple Sclerosis Drugs Treatment Market
o Rest of Europe Multiple Sclerosis Drugs Treatment Market
o Asia-Pacific
§ Asia-Pacific Multiple Sclerosis Drugs Treatment Market, By Country
o ChinaMultiple Sclerosis Drugs Treatment Market
o Japan Multiple Sclerosis Drugs Treatment Market
o South KoreaMultiple Sclerosis Drugs Treatment Market
o India Multiple Sclerosis Drugs Treatment Market
o Southeast AsiaMultiple Sclerosis Drugs Treatment Market
o Rest of Asia-Pacific Multiple Sclerosis Drugs Treatment Market
o South America
§ South AmericaMultiple Sclerosis Drugs Treatment Market
o Brazil Multiple Sclerosis Drugs Treatment Market
o ArgentinaMultiple Sclerosis Drugs Treatment Market
o ColumbiaMultiple Sclerosis Drugs Treatment Market
o Rest of South America Multiple Sclerosis Drugs Treatment Market
o Middle East and Africa
§ Middle East and AfricaMultiple Sclerosis Drugs Treatment Market
o Saudi ArabiaMultiple Sclerosis Drugs Treatment Market
o UAEMultiple Sclerosis Drugs Treatment Market
o EgyptMultiple Sclerosis Drugs Treatment Market
o NigeriaMultiple Sclerosis Drugs Treatment Market
o South Africa Multiple Sclerosis Drugs Treatment Market
o Rest of MEA Multiple Sclerosis Drugs Treatment Market
Table of Contents:
1. Introduction
1.1. Report Description
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market Status and Outlook (2017-2027)
4.1.2. Canada Market Status and Outlook (2017-2027)
4.1.3. Mexico Market Status and Outlook (2017-2027)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market Status and Outlook (2017-2027)
4.2.2. France Market Status and Outlook (2017-2027)
4.2.3. UK Market Status and Outlook (2017-2027)
4.2.4. Russia Market Status and Outlook (2017-2027)
4.2.5. Italy Market Status and Outlook (2017-2027)
4.2.6. Rest of Europe Market Status and Outlook (2017-2027)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market Status and Outlook (2017-2027)
4.3.2. Japan Market Status and Outlook (2017-2027)
4.3.3. Korea Market Status and Outlook (2017-2027)
4.3.4. India Market Status and Outlook (2017-2027)
4.3.5. Southeast Asia Market Status and Outlook (2017-2027)
4.3.6. Rest of Asia-Pacific Market Status and Outlook (2017-2027)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market Status and Outlook (2017-2027)
4.4.2. Argentina Market Status and Outlook (2017-2027)
4.4.3. Columbia Market Status and Outlook (2017-2027)
4.4.4. Rest of South America Market Status and Outlook (2017-2027)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market Status and Outlook (2017-2027)
4.5.2. United Arab Emirates Market Status and Outlook (2017-2027)
4.5.3. Egypt Market Status and Outlook (2017-2027)
4.5.4. Nigeria Market Status and Outlook (2017-2027)
4.5.5. South Africa Market Status and Outlook (2017-2027)
4.5.6. Turkey Market Status and Outlook (2017-2027)
4.5.7. Rest of Middle East and Africa Market Status and Outlook (2017-2027)
5. Multiple Sclerosis Drugs Treatment Market, By Type
5.1. Introduction
5.2. Global Multiple Sclerosis Drugs Treatment Revenue and Market Share by Type (2017-2021)
5.2.1. Global Multiple Sclerosis Drugs Treatment Revenue and Revenue Share by Type (2017-2021)
5.3. Immunomodulator
5.3.1. Global Immunomodulator Revenue and Growth Rate (2017-2021)
5.4. Interferon
5.4.1. Global Interferon Revenue and Growth Rate (2017-2021)
5.5. Immunosuppressant
5.5.1. Global Immunosuppressant Revenue and Growth Rate (2017-2021)
6. Multiple Sclerosis Drugs Treatment Market, By Application
6.1. Introduction
6.2. Global Multiple Sclerosis Drugs Treatment Revenue and Market Share by Application (2017-2021)
6.2.1. Global Multiple Sclerosis Drugs Treatment Revenue and Revenue Share by Application (2017-2021)
6.3. Retail Pharmacy
6.3.1. Global Retail Pharmacy Revenue and Growth Rate (2017-2021)
6.4. Hospital Pharmacy
6.4.1. Global Hospital Pharmacy Revenue and Growth Rate (2017-2021)
6.5. Online Pharmacy
6.5.1. Global Online Pharmacy Revenue and Growth Rate (2017-2021)
7. Multiple Sclerosis Drugs Treatment Market, By Region
7.1. Introduction
7.2. Global Multiple Sclerosis Drugs Treatment Revenue and Market Share by Regions
7.2.1. Global Multiple Sclerosis Drugs Treatment Revenue by Regions (2017-2021)
7.3. North America Multiple Sclerosis Drugs Treatment by Countries
7.3.1. North America Multiple Sclerosis Drugs Treatment Revenue and Growth Rate (2017-2021)
7.3.2. North America Multiple Sclerosis Drugs Treatment Revenue (Million USD) by Countries (2017-2021)
7.3.3. United States
7.3.3.1. United States Multiple Sclerosis Drugs Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.3.4. Canada
7.3.4.1. Canada Multiple Sclerosis Drugs Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.3.5. Mexico
7.3.5.1. Mexico Multiple Sclerosis Drugs Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.4. Europe Multiple Sclerosis Drugs Treatment by Countries
7.4.1. Europe Multiple Sclerosis Drugs Treatment Revenue and Growth Rate (2017-2021)
7.4.2. Europe Multiple Sclerosis Drugs Treatment Revenue (Million USD) by Countries (2017-2021)
7.4.3. Germany
7.4.3.1. Germany Multiple Sclerosis Drugs Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.4. France
7.4.4.1. France Multiple Sclerosis Drugs Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.5. UK
7.4.5.1. UK Multiple Sclerosis Drugs Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.6. Russia
7.4.6.1. Russia Multiple Sclerosis Drugs Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.7. Italy
7.4.7.1. Italy Multiple Sclerosis Drugs Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.8. Rest of Europe
7.4.8.1. Rest of Europe Multiple Sclerosis Drugs Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.5. Asia-Pacific Multiple Sclerosis Drugs Treatment by Countries
7.5.1. Asia-Pacific Multiple Sclerosis Drugs Treatment Revenue and Growth Rate (2017-2021)
7.5.2. Asia-Pacific Multiple Sclerosis Drugs Treatment Revenue (Million USD) by Countries (2017-2021)
7.5.3. China
7.5.3.1. China Multiple Sclerosis Drugs Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.4. Japan
7.5.4.1. Japan Multiple Sclerosis Drugs Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.5. Korea
7.5.5.1. Korea Multiple Sclerosis Drugs Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.6. India
7.5.6.1. India Multiple Sclerosis Drugs Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.7. Southeast Asia
7.5.7.1. Southeast Asia Multiple Sclerosis Drugs Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.8. Rest of Asia-Pacific
7.5.8.1. Rest of Asia-Pacific Multiple Sclerosis Drugs Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.6. South America Multiple Sclerosis Drugs Treatment by Countries
7.6.1. South America Multiple Sclerosis Drugs Treatment Revenue and Growth Rate (2017-2021)
7.6.2. South America Multiple Sclerosis Drugs Treatment Revenue (Million USD) by Countries (2017-2021)
7.6.3. Brazil
7.6.3.1. Brazil Multiple Sclerosis Drugs Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.6.4. Argentina
7.6.4.1. Argentina Multiple Sclerosis Drugs Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.6.5. Columbia
7.6.5.1. Columbia Multiple Sclerosis Drugs Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.6.6. Rest of South America
7.6.6.1. Rest of South America Multiple Sclerosis Drugs Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.7. Middle East and Africa Multiple Sclerosis Drugs Treatment by Countries
7.7.1. Middle East and Africa Multiple Sclerosis Drugs Treatment Revenue and Growth Rate (2017-2021)
7.7.2. Middle East and Africa Multiple Sclerosis Drugs Treatment Revenue (Million USD) by Countries (2017-2021)
7.7.3. Saudi Arabia
7.7.3.1. Saudi Arabia Multiple Sclerosis Drugs Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.4. United Arab Emirates
7.7.4.1. United Arab Emirates Multiple Sclerosis Drugs Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.5. Egypt
7.7.5.1. Egypt Multiple Sclerosis Drugs Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.6. Nigeria
7.7.6.1. Nigeria Multiple Sclerosis Drugs Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.7. South Africa
7.7.7.1. South Africa Multiple Sclerosis Drugs Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.8. Turkey
7.7.8.1. Turkey Multiple Sclerosis Drugs Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.9. Rest of Middle East and Africa
7.7.9.1. Rest of Middle East and Africa Multiple Sclerosis Drugs Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
8. Company Profiles
8.1. Roche
8.1.1. Business Overview
8.1.2. Service Portfolio
8.1.3. Strategic Developments
8.1.4. Financial Overview
8.2. Teva Pharmaceutical
8.2.1. Business Overview
8.2.2. Service Portfolio
8.2.3. Strategic Developments
8.2.4. Financial Overview
8.3. Pfizer
8.3.1. Business Overview
8.3.2. Service Portfolio
8.3.3. Strategic Developments
8.3.4. Financial Overview
8.4. Biogen
8.4.1. Business Overview
8.4.2. Service Portfolio
8.4.3. Strategic Developments
8.4.4. Financial Overview
8.5. Merck
8.5.1. Business Overview
8.5.2. Service Portfolio
8.5.3. Strategic Developments
8.5.4. Financial Overview
8.6. Bayer
8.6.1. Business Overview
8.6.2. Service Portfolio
8.6.3. Strategic Developments
8.6.4. Financial Overview
8.7. Novartis
8.7.1. Business Overview
8.7.2. Service Portfolio
8.7.3. Strategic Developments
8.7.4. Financial Overview
8.8. Acorda Therapeutics
8.8.1. Business Overview
8.8.2. Service Portfolio
8.8.3. Strategic Developments
8.8.4. Financial Overview
8.9. Sanofi
8.9.1. Business Overview
8.9.2. Service Portfolio
8.9.3. Strategic Developments
8.9.4. Financial Overview
9. Multiple Sclerosis Drugs Treatment Market Forecast (2022-2027)
9.1. Global Multiple Sclerosis Drugs Treatment Revenue (Millions USD) and Growth Rate (2022-2027)
9.2. Multiple Sclerosis Drugs Treatment Market Forecast by Regions (2022-2027)
9.2.1. North America Multiple Sclerosis Drugs Treatment Market Forecast (2022-2027)
9.2.1.1. United States Multiple Sclerosis Drugs Treatment Market Forecast (2022-2027)
9.2.1.2. Canada Multiple Sclerosis Drugs Treatment Market Forecast (2022-2027)
9.2.1.3. Mexico Multiple Sclerosis Drugs Treatment Market Forecast (2022-2027)
9.2.2. Europe Multiple Sclerosis Drugs Treatment Market Forecast (2022-2027)
9.2.2.1. Germany Multiple Sclerosis Drugs Treatment Market Forecast (2022-2027)
9.2.2.2. France Multiple Sclerosis Drugs Treatment Market Forecast (2022-2027)
9.2.2.3. UK Multiple Sclerosis Drugs Treatment Market Forecast (2022-2027)
9.2.2.4. Russia Multiple Sclerosis Drugs Treatment Market Forecast (2022-2027)
9.2.2.5. Italy Multiple Sclerosis Drugs Treatment Market Forecast (2022-2027)
9.2.2.6. Rest of Europe Multiple Sclerosis Drugs Treatment Market Forecast (2022-2027)
9.2.3. Asia-Pacific Multiple Sclerosis Drugs Treatment Market Forecast (2022-2027)
9.2.3.1. China Multiple Sclerosis Drugs Treatment Market Forecast (2022-2027)
9.2.3.2. Japan Multiple Sclerosis Drugs Treatment Market Forecast (2022-2027)
9.2.3.3. Korea Multiple Sclerosis Drugs Treatment Market Forecast (2022-2027)
9.2.3.4. India Multiple Sclerosis Drugs Treatment Market Forecast (2022-2027)
9.2.3.5. Southeast Asia Multiple Sclerosis Drugs Treatment Market Forecast (2022-2027)
9.2.3.6. Rest of Asia-Pacific Multiple Sclerosis Drugs Treatment Market Forecast (2022-2027)
9.2.4. South America Multiple Sclerosis Drugs Treatment Market Forecast (2022-2027)
9.2.4.1. Brazil Multiple Sclerosis Drugs Treatment Market Forecast (2022-2027)
9.2.4.2. Argentina Multiple Sclerosis Drugs Treatment Market Forecast (2022-2027)
9.2.4.3. Columbia Multiple Sclerosis Drugs Treatment Market Forecast (2022-2027)
9.2.4.4. Rest of South America Multiple Sclerosis Drugs Treatment Market Forecast (2022-2027)
9.2.5. Middle East and Africa Multiple Sclerosis Drugs Treatment Market Forecast (2022-2027)
9.2.5.1. Saudi Arabia Multiple Sclerosis Drugs Treatment Market Forecast (2022-2027)
9.2.5.2. United Arab Emirates Multiple Sclerosis Drugs Treatment Market Forecast (2022-2027)
9.2.5.3. Egypt Multiple Sclerosis Drugs Treatment Market Forecast (2022-2027)
9.2.5.4. Nigeria Multiple Sclerosis Drugs Treatment Market Forecast (2022-2027)
9.2.5.5. South Africa Multiple Sclerosis Drugs Treatment Market Forecast (2022-2027)
9.2.5.6. Turkey Multiple Sclerosis Drugs Treatment Market Forecast (2022-2027)
9.2.5.7. Rest of Middle East and Africa Multiple Sclerosis Drugs Treatment Market Forecast (2022-2027)
9.3. Multiple Sclerosis Drugs Treatment Market Forecast by Type (2022-2027)
9.3.1. Multiple Sclerosis Drugs Treatment Forecast by Type (2022-2027)
9.3.2. Multiple Sclerosis Drugs Treatment Market Share Forecast by Type (2022-2027)
9.4. Multiple Sclerosis Drugs Treatment Market Forecast by Application (2022-2027)
9.4.1. Multiple Sclerosis Drugs Treatment Forecast by Application (2022-2027)
9.4.2. Multiple Sclerosis Drugs Treatment Market Share Forecast by Application (2022-2027)
List of Tables
List of Tables and Figures:
Figure United States Multiple Sclerosis Drugs Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Canada Multiple Sclerosis Drugs Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Mexico Multiple Sclerosis Drugs Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Germany Multiple Sclerosis Drugs Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure France Multiple Sclerosis Drugs Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure UK Multiple Sclerosis Drugs Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Russia Multiple Sclerosis Drugs Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Italy Multiple Sclerosis Drugs Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Europe Multiple Sclerosis Drugs Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure China Multiple Sclerosis Drugs Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Japan Multiple Sclerosis Drugs Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Korea Multiple Sclerosis Drugs Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure India Multiple Sclerosis Drugs Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Southeast Asia Multiple Sclerosis Drugs Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Asia-Pacific Multiple Sclerosis Drugs Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Brazil Multiple Sclerosis Drugs Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Argentina Multiple Sclerosis Drugs Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Columbia Multiple Sclerosis Drugs Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of South America Multiple Sclerosis Drugs Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Saudi Arabia Multiple Sclerosis Drugs Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure United Arab Emirates Multiple Sclerosis Drugs Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Egypt Multiple Sclerosis Drugs Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Nigeria Multiple Sclerosis Drugs Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure South Africa Multiple Sclerosis Drugs Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Turkey Multiple Sclerosis Drugs Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Middle East and Africa Multiple Sclerosis Drugs Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Table Global Multiple Sclerosis Drugs Treatment Revenue and Revenue Share by Type (2017-2019)
Figure Global Immunomodulator Revenue and Growth Rate (2017-2019)
Figure Global Interferon Revenue and Growth Rate (2017-2019)
Figure Global Immunosuppressant Revenue and Growth Rate (2017-2019)
Table Global Multiple Sclerosis Drugs Treatment Revenue and Revenue Share by Application (2017-2019)
Figure Global Retail Pharmacy Revenue and Growth Rate (2017-2019)
Figure Global Hospital Pharmacy Revenue and Growth Rate (2017-2019)
Figure Global Online Pharmacy Revenue and Growth Rate (2017-2019)
Table Global Multiple Sclerosis Drugs Treatment Revenue by Regions (2017-2019)
Figure North America Multiple Sclerosis Drugs Treatment Growth Rate (2017-2019)
Figure North America Multiple Sclerosis Drugs Treatment Revenue and Growth Rate (2017-2019)
Figure North America Multiple Sclerosis Drugs Treatment by Countries (2017-2019)
Figure North America Multiple Sclerosis Drugs Treatment Revenue (Million USD) by Countries (2017-2019)
Figure United States Multiple Sclerosis Drugs Treatment Growth Rate (2017-2019)
Figure United States Multiple Sclerosis Drugs Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Canada Multiple Sclerosis Drugs Treatment Growth Rate (2017-2019)
Figure Canada Multiple Sclerosis Drugs Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Mexico Multiple Sclerosis Drugs Treatment Growth Rate (2017-2019)
Figure Mexico Multiple Sclerosis Drugs Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Europe Multiple Sclerosis Drugs Treatment Growth Rate (2017-2019)
Figure Europe Multiple Sclerosis Drugs Treatment Revenue and Growth Rate (2017-2019)
Figure Europe Multiple Sclerosis Drugs Treatment by Countries (2017-2019)
Figure Europe Multiple Sclerosis Drugs Treatment Revenue (Million USD) by Countries (2017-2019)
Figure Germany Multiple Sclerosis Drugs Treatment Growth Rate (2017-2019)
Figure Germany Multiple Sclerosis Drugs Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure France Multiple Sclerosis Drugs Treatment Growth Rate (2017-2019)
Figure France Multiple Sclerosis Drugs Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure UK Multiple Sclerosis Drugs Treatment Growth Rate (2017-2019)
Figure UK Multiple Sclerosis Drugs Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Russia Multiple Sclerosis Drugs Treatment Growth Rate (2017-2019)
Figure Russia Multiple Sclerosis Drugs Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Italy Multiple Sclerosis Drugs Treatment Growth Rate (2017-2019)
Figure Italy Multiple Sclerosis Drugs Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of Europe Multiple Sclerosis Drugs Treatment Growth Rate (2017-2019)
Figure Rest of Europe Multiple Sclerosis Drugs Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Asia-Pacific Multiple Sclerosis Drugs Treatment Growth Rate (2017-2019)
Figure Asia-Pacific Multiple Sclerosis Drugs Treatment Revenue and Growth Rate (2017-2019)
Figure Asia-Pacific Multiple Sclerosis Drugs Treatment by Countries (2017-2019)
Figure Asia-Pacific Multiple Sclerosis Drugs Treatment Revenue (Million USD) by Countries (2017-2019)
Figure China Multiple Sclerosis Drugs Treatment Growth Rate (2017-2019)
Figure China Multiple Sclerosis Drugs Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Japan Multiple Sclerosis Drugs Treatment Growth Rate (2017-2019)
Figure Japan Multiple Sclerosis Drugs Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Korea Multiple Sclerosis Drugs Treatment Growth Rate (2017-2019)
Figure Korea Multiple Sclerosis Drugs Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure India Multiple Sclerosis Drugs Treatment Growth Rate (2017-2019)
Figure India Multiple Sclerosis Drugs Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Southeast Asia Multiple Sclerosis Drugs Treatment Growth Rate (2017-2019)
Figure Southeast Asia Multiple Sclerosis Drugs Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of Asia-Pacific Multiple Sclerosis Drugs Treatment Growth Rate (2017-2019)
Figure Rest of Asia-Pacific Multiple Sclerosis Drugs Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure South America Multiple Sclerosis Drugs Treatment Growth Rate (2017-2019)
Figure South America Multiple Sclerosis Drugs Treatment Revenue and Growth Rate (2017-2019)
Figure South America Multiple Sclerosis Drugs Treatment by Countries (2017-2019)
Figure South America Multiple Sclerosis Drugs Treatment Revenue (Million USD) by Countries (2017-2019)
Figure Brazil Multiple Sclerosis Drugs Treatment Growth Rate (2017-2019)
Figure Brazil Multiple Sclerosis Drugs Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Argentina Multiple Sclerosis Drugs Treatment Growth Rate (2017-2019)
Figure Argentina Multiple Sclerosis Drugs Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Columbia Multiple Sclerosis Drugs Treatment Growth Rate (2017-2019)
Figure Columbia Multiple Sclerosis Drugs Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of South America Multiple Sclerosis Drugs Treatment Growth Rate (2017-2019)
Figure Rest of South America Multiple Sclerosis Drugs Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Middle East and Africa Multiple Sclerosis Drugs Treatment Growth Rate (2017-2019)
Figure Middle East and Africa Multiple Sclerosis Drugs Treatment Revenue and Growth Rate (2017-2019)
Figure Middle East and Africa Multiple Sclerosis Drugs Treatment by Countries (2017-2019)
Figure Middle East and Africa Multiple Sclerosis Drugs Treatment Revenue (Million USD) by Countries (2017-2019)
Figure Saudi Arabia Multiple Sclerosis Drugs Treatment Growth Rate (2017-2019)
Figure Saudi Arabia Multiple Sclerosis Drugs Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure United Arab Emirates Multiple Sclerosis Drugs Treatment Growth Rate (2017-2019)
Figure United Arab Emirates Multiple Sclerosis Drugs Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Egypt Multiple Sclerosis Drugs Treatment Growth Rate (2017-2019)
Figure Egypt Multiple Sclerosis Drugs Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Nigeria Multiple Sclerosis Drugs Treatment Growth Rate (2017-2019)
Figure Nigeria Multiple Sclerosis Drugs Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure South Africa Multiple Sclerosis Drugs Treatment Growth Rate (2017-2019)
Figure South Africa Multiple Sclerosis Drugs Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Turkey Multiple Sclerosis Drugs Treatment Growth Rate (2017-2019)
Figure Turkey Multiple Sclerosis Drugs Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of Middle East and Africa Multiple Sclerosis Drugs Treatment Growth Rate (2017-2019)
Figure Rest of Middle East and Africa Multiple Sclerosis Drugs Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Table Roche Multiple Sclerosis Drugs Treatment Financial Overview
Table Teva Pharmaceutical Multiple Sclerosis Drugs Treatment Financial Overview
Table Pfizer Multiple Sclerosis Drugs Treatment Financial Overview
Table Biogen Multiple Sclerosis Drugs Treatment Financial Overview
Table Merck Multiple Sclerosis Drugs Treatment Financial Overview
Table Bayer Multiple Sclerosis Drugs Treatment Financial Overview
Table Novartis Multiple Sclerosis Drugs Treatment Financial Overview
Table Acorda Therapeutics Multiple Sclerosis Drugs Treatment Financial Overview
Table Sanofi Multiple Sclerosis Drugs Treatment Financial Overview
Figure Global Multiple Sclerosis Drugs Treatment Revenue (Millions USD) and Growth Rate (2019-2027)
Table Multiple Sclerosis Drugs Treatment Market Forecast by Regions (2019-2027)
Figure North America Multiple Sclerosis Drugs Treatment Market Forecast (2019-2027)
Figure United States Multiple Sclerosis Drugs Treatment Market Forecast (2019-2027)
Figure Canada Multiple Sclerosis Drugs Treatment Market Forecast (2019-2027)
Figure Mexico Multiple Sclerosis Drugs Treatment Market Forecast (2019-2027)
Figure Europe Multiple Sclerosis Drugs Treatment Market Forecast (2019-2027)
Figure Germany Multiple Sclerosis Drugs Treatment Market Forecast (2019-2027)
Figure France Multiple Sclerosis Drugs Treatment Market Forecast (2019-2027)
Figure UK Multiple Sclerosis Drugs Treatment Market Forecast (2019-2027)
Figure Russia Multiple Sclerosis Drugs Treatment Market Forecast (2019-2027)
Figure Italy Multiple Sclerosis Drugs Treatment Market Forecast (2019-2027)
Figure Rest of Europe Multiple Sclerosis Drugs Treatment Market Forecast (2019-2027)
Figure Asia-Pacific Multiple Sclerosis Drugs Treatment Market Forecast (2019-2027)
Figure China Multiple Sclerosis Drugs Treatment Market Forecast (2019-2027)
Figure Japan Multiple Sclerosis Drugs Treatment Market Forecast (2019-2027)
Figure Korea Multiple Sclerosis Drugs Treatment Market Forecast (2019-2027)
Figure India Multiple Sclerosis Drugs Treatment Market Forecast (2019-2027)
Figure Southeast Asia Multiple Sclerosis Drugs Treatment Market Forecast (2019-2027)
Figure Rest of Asia-Pacific Multiple Sclerosis Drugs Treatment Market Forecast (2019-2027)
Figure South America Multiple Sclerosis Drugs Treatment Market Forecast (2019-2027)
Figure Brazil Multiple Sclerosis Drugs Treatment Market Forecast (2019-2027)
Figure Argentina Multiple Sclerosis Drugs Treatment Market Forecast (2019-2027)
Figure Columbia Multiple Sclerosis Drugs Treatment Market Forecast (2019-2027)
Figure Rest of South America Multiple Sclerosis Drugs Treatment Market Forecast (2019-2027)
Figure Middle East and Africa Multiple Sclerosis Drugs Treatment Market Forecast (2019-2027)
Figure Saudi Arabia Multiple Sclerosis Drugs Treatment Market Forecast (2019-2027)
Figure United Arab Emirates Multiple Sclerosis Drugs Treatment Market Forecast (2019-2027)
Figure Egypt Multiple Sclerosis Drugs Treatment Market Forecast (2019-2027)
Figure Nigeria Multiple Sclerosis Drugs Treatment Market Forecast (2019-2027)
Figure South Africa Multiple Sclerosis Drugs Treatment Market Forecast (2019-2027)
Figure Turkey Multiple Sclerosis Drugs Treatment Market Forecast (2019-2027)
Figure Rest of Middle East and Africa Multiple Sclerosis Drugs Treatment Market Forecast (2019-2027)
Figure Global Multiple Sclerosis Drugs Treatment Forecast by Type (2019-2027)
Figure Global Multiple Sclerosis Drugs Treatment Market Share Forecast by Type (2019-2027)
Figure Global Multiple Sclerosis Drugs Treatment Forecast by Type (2019-2027)
Figure Global Multiple Sclerosis Drugs Treatment Forecast by Application (2019-2027)
Figure Global Multiple Sclerosis Drugs Treatment Market Share Forecast by Application (2019-2027)
Figure Global Multiple Sclerosis Drugs Treatment Forecast by Application (2019-2027)
Please Note: Data related to the Companies are subject to Availability.
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|